The PRPF31 (Pre-mRNA Processing Factor 31) gene encodes a core component of the U4/U6.U5 tri-snRNP complex, which is essential for pre-mRNA splicing. PRPF31 is a spliceosomal protein that plays a critical role in the spliceosome assembly and catalytic steps during precursor messenger RNA processing. Mutations in PRPF31 are classically associated with retinitis pigmentosa, but emerging evidence suggests broader implications for neurodegenerative diseases through its essential role in neuronal RNA processing and splicing regulation.
PRPF31 is a member of the PRP (Pre-mRNA processing) protein family and functions as an essential spliceosome component. The protein is conserved across eukaryotes and is ubiquitously expressed, with particularly high expression in neuronal tissues. The spliceosome is the large ribonucleoprotein complex responsible for removing introns from pre-mRNA, and PRPF31 is one of the key proteins that stabilize the catalytic core of this machinery.
While PRPF31 mutations are most strongly associated with retinitis pigmentosa—a hereditary retinal degeneration leading to progressive vision loss—recent research has highlighted its potential role in neurodegeneration more broadly. Neurons are particularly dependent on precise RNA splicing due to their complex and specialized gene expression patterns, and any disruption in splicing machinery can have profound effects on neuronal survival and function.
|
|
| Gene Symbol |
PRPF31 |
| Gene Name |
Pre-mRNA Processing Factor 31 |
| Chromosome |
19q13.42 |
| NCBI Gene ID |
26121 |
| OMIM |
607395 |
| Ensembl ID |
ENSG00000105618 |
| UniProt |
O94973 |
| Associated Diseases |
Retinitis Pigmentosa, Retinal Degeneration, Potential Neurodegeneration |
PRPF31 is a core component of the U4/U6.U5 tri-snRNP (small nuclear ribonucleoprotein particle), which forms the major building block of the spliceosome. The tri-snRNP contains:
- U4 snRNA — serves as an intronic sequence placeholder
- U6 snRNA — the catalytic component of the spliceosome
- U5 snRNA — recognizes the 5' and 3' splice sites
- PRPF31 — stabilizes the U4/U6 interaction and facilitates spliceosome assembly
- Other proteins — including PRPF3, PRPF4, and ABC1
PRPF31 contains an N-terminal low-complexity region and a C-terminal domain that interacts with other tri-snRNP components. The protein facilitates the proper folding and base-pairing of U4 and U6 snRNAs, which is essential for the catalytic activation of the spliceosome.
The spliceosome undergoes a series of coordinated assembly steps:
- E complex — U1 snRNP recognizes the 5' splice site
- A complex — U2 snRNP displaces branch point binding proteins and binds the branch point
- B complex — U4/U6.U5 tri-snRNP joins to form the pre-catalytic spliceosome
- B complex* — catalytic activation occurs (PRPF31 plays a key role here)
- C complex — first transesterification reaction (5' splice site cleavage)
- C complex* — second transesterification reaction (exon ligation)
- Post-spliceosome — release of the spliced mRNA and disassembly
PRPF31 is particularly important for the B to B* transition, where the spliceosome becomes catalytically active.
Neurons have particularly complex splicing patterns, with extensive alternative splicing generating diverse protein isoforms essential for synaptic function, neuronal development, and circuit formation. PRPF31-mediated splicing affects:
- Synaptic proteins — NMDA receptor subunits, AMPA receptor variants, scaffolding proteins
- Ion channels — voltage-gated calcium and potassium channel isoforms
- Axon guidance molecules — netrins, semaphorins, ephrins
- Transcription factors — neuronal specific splicing regulators
Dysregulation of any of these processes can contribute to neurodegenerative processes.
PRPF31 mutations are among the most common causes of autosomal dominant retinitis pigmentosa (ADRP). The disease mechanism involves:
- ** haploinsufficiency** — 50% reduction in functional PRPF31 leads to photoreceptor degeneration
- Splicing defects — mutant PRPF31 produces abnormal spliceosome function
- Photoreceptor vulnerability — rods are particularly sensitive to splicing disruption
Over 100 pathogenic variants in PRPF31 have been identified, including missense mutations, nonsense mutations, splice-site mutations, and deletions.
While not classically considered a neurodegeneration gene, PRPF31's essential function in RNA splicing suggests potential roles in:
- Amyotrophic Lateral Sclerosis (ALS) — splicing defects have been documented in ALS patient tissue
- Frontotemporal Dementia (FTD) — RNA processing dysfunction is a common feature
- Spinal Muscular Atrophy — splicing machinery defects contribute to disease
- Alzheimer's Disease — aberrant splicing has been reported in AD brain tissue
The spliceosome is increasingly recognized as a therapeutic target in neurodegeneration, with several approaches in development:
- ASO (Antisense oligonucleotide) therapy — correct aberrant splicing
- Small molecule spliceosome modulators — enhance splicing efficiency
- Gene therapy — deliver functional PRPF31
Emerging evidence links PRPF31 to Alzheimer's disease pathogenesis:
Splicing Dysregulation in AD:
- Genome-wide splicing analysis reveals widespread abnormalities in AD brain
- PRPF31 expression is reduced in AD temporal cortex
- Affected transcripts include those involved in synaptic function
- Tau pathology correlates with splicing defects
Key Splicing Targets:
- APP alternative splicing generates toxic isoforms
- Tau exon 10 mis-splicing affects isoform ratios
- Synaptic protein isoforms altered in disease
- Mitochondrial transcripts affected
PRPF31 may contribute to Parkinson's disease through RNA processing mechanisms:
Altered Splicing Patterns:
- PD brain tissue shows distinct splicing signatures
- Mitochondrial function transcripts affected
- Autophagy-related genes mis-spliced
- Synaptic transmission transcripts altered
Alpha-Synuclein Connection:
- SNCA splicing may be PRPF31-dependent
- Aggregation-prone isoforms potentially regulated
- RNA binding protein interactions
- Stress granule formation link
¶ PRPF31 in ALS and FTD
The spliceosome is directly implicated in ALS and FTD pathogenesis:
RNA Processing Defects:
- C9orf72 hexanucleotide expansion affects splicing
- PRPF31 variants modify disease risk
- TDP-43 pathology impacts spliceosome function
- Loss of nuclear RNA processing
Therapeutic Implications:
- ASO therapy targeting specific splicing events
- Spliceosome-modulating drugs
- Gene replacement strategies
PRPF31 is expressed in virtually all tissues, with highest levels in:
- Retina and photoreceptor cells
- Brain (cerebral cortex, hippocampus)
- Testis
- Heart and skeletal muscle
- Nuclear — PRPF31 localizes to nuclear speckles, where spliceosome assembly occurs
- Nucleolus — some accumulation in nucleolar regions
- Cytoplasmic — limited cytoplasmic localization in neurons
PRPF31 expression is regulated by:
- Transcription factors — SP1, AP-2 influence basal expression
- Cell cycle — expression peaks in S phase
- Stress responses — heat shock and oxidative stress affect levels
- Developmental stage — higher expression during neural development
PRPF31 is part of the major spliceosome pathway, interacting with:
- U1 snRNP (5' splice site recognition)
- U2 snRNP (branch point binding)
- U4/U6.U5 tri-snRNP (catalytic core)
- NTC (Nineteen Complex) — required for spliceosome activation
PRPF31 participates in:
- Pre-mRNA splicing
- Alternative splicing regulation
- mRNA export (coupled to splicing)
- NMD (nonsense-mediated decay) coupling
¶ Spliceosome Assembly and Catalysis
PRPF31 plays essential roles in the spliceosome catalytic cycle:
Tri-snRNP Integration:
- PRPF31 stabilizes the U4/U6.U5 tri-snRNP
- Facilitates proper snRNA base-pairing
- Required for spliceosome activation
- ATP-dependent conformational changes
Catalytic Activation:
- B to B* complex transition requires PRPF31
- Release of U4 snRNA enables catalysis
- Quality control checkpoint function
- Disassembly and recycling
Neurons have particularly complex splicing requirements:
Synaptic Protein Isoforms:
- NMDA and AMPA receptor subunit variants
- Synaptic scaffolding proteins
- Ion channel diversity
- Activity-dependent splice variants
Developmental Splicing Programs:
- Neuron-specific splicing factors
- Alternative exon usage
- Splicing factor expression changes in aging
- Disease-related splicing alterations
¶ PRPF31 and Protein Homeostasis
Aberrant splicing contributes to protein homeostasis collapse in neurodegeneration:
Protein Aggregate Formation:
- Mis-spliced proteins more prone to misfolding
- Clearance pathway dysfunction
- Sequestration of quality control machinery
- Propagation of proteostatic stress
Autophagy Regulation:
- ATG transcripts alternatively spliced
- Lysosomal function affected
- Aggregate clearance impaired
- Cellular stress response
PRPF31 functions within the context of larger RNA-protein complexes:
Stress Granules:
- Splicing factors accumulate in stress granules
- PRPF31 localization during cellular stress
- Connection to FTD pathology
- Therapeutic targeting potential
Nuclear Speckles:
- Storage and assembly sites for spliceosome components
- Dynamic trafficking between compartments
- Age-related changes
- Disease-related disruption
Aging affects spliceosome function and PRPF31 activity:
Spliceosome Aging:
- Declined splicing fidelity with age
- Accumulation of splicing errors
- Increased aberrant splicing events
- Cellular consequences
Neuronal Vulnerability:
- Post-mitotic neurons cannot dilute errors
- Cumulative splicing defects
- Synaptic dysfunction
- Age-related disease onset
Aging-related splicing changes offer therapeutic opportunities:
Splicing Enhancement:
- Compounds that boost spliceosome function
- Targeting age-related splicing decline
- Preventive interventions
- Disease modification
Error Correction:
- ASO-mediated splice correction
- Gene therapy approaches
- Protein-based interventions
¶ Biomarkers and Diagnostics
Splicing patterns may serve as disease biomarkers:
Blood-Based Markers:
- Splice variant detection in PBMCs
- Correlation with disease state
- Non-invasive monitoring
- Clinical utility studies
CSF Markers:
- Neuron-derived splicing products
- Disease-specific patterns
- Prognostic value
- Therapeutic monitoring
PRPF31 testing considerations:
Retinitis Pigmentosa:
- Diagnostic testing available
- Family counseling
- Genotype-phenotype correlations
- Treatment planning
Neurodegeneration Risk:
- Research use only currently
- Variant interpretation challenges
- Multiple genetic contributors
- Polygenic risk considerations
Prpf31 Mutant Mice:
- Haploinsufficient mice model PRPF31 RP
- Photoreceptor degeneration
- Retinal function decline
- Splicing defects in neural tissues
Conditional Knockouts:
- Neuron-specific deletion models
- Disease mechanism studies
- Therapeutic testing platforms
Patient-Derived Cells:
- iPSC-derived retinal organoids
- Neuronal differentiation protocols
- Disease modeling
- Gene correction studies
Splicing Assays:
- Minigene reporter systems
- RNA-seq analysis
- spliceosome activity measurements
The spliceosome represents a promising therapeutic target:
ASO Therapy:
- Antisense oligonucleotides correct aberrant splicing
- Splice-switching oligonucleotides
- Tissue delivery optimization
- Clinical trials in progress
Small Molecule Modulators:
- Spliceosome-enhancing compounds
- Selective splicing modulators
- Combination approaches
- Safety considerations
Viral Vector Delivery:
- AAV-mediated PRPF31 expression
- Optimized promoters for retinal expression
- Dose-finding studies
- Clinical translation
CRISPR-Based Approaches:
- Allele-specific editing
- Splice-site correction
- Regulatory element targeting
¶ Clinical Trial Landscape
Current clinical approaches targeting RNA splicing:
Retinitis Pigmentosa:
- Gene replacement trials ongoing
- AAV-PRPF31 safety studies
- Visual acuity endpoints
- Long-term follow-up
Neurodegeneration:
- ASO trials for other splicing factors
- Biomarker development
- Patient selection criteria
- Combination approaches
FDA Pathways:
- Orphan drug designation
- Accelerated approval
- Biomarker-based endpoints
- Pediatric considerations
Global Perspectives:
- EMA COMP designation
- Japanese conditional approval
- International collaboration
Given PRPF31's essential role in RNA splicing, therapeutic strategies are being developed:
- Antisense oligonucleotide (ASO) therapy: Correct aberrant splicing patterns
- Small molecule spliceosome modulators: Enhance splicing efficiency
- Gene therapy: Deliver functional PRPF31 to affected tissues
Current research directions include:
¶ Mermaid Diagram: PRPF31 Functions and Disease
flowchart TD
A["PRPF31 Protein"] --> B["Spliceosome Assembly"]
A --> C["U4/U6.U5 Tri-snRNP"]
A --> D["Catalytic Activation"]
B --> B1["B Complex Formation"]
B1 --> B2["Pre-catalytic Spliceosome"]
B2 --> B3["B* Complex (Active)"]
C --> C1["U4 snRNA Stability"]
C1 --> C2["U6 snRNA Interaction"]
D --> D1["First Transesterification"]
D --> D2["Second Transesterification"]
D1 --> D3["mRNA Splicing"]
B3 --> E["Normal RNA Processing"]
D3 --> E
F["PRPF31 Mutations"] --> G["Retinitis Pigmentosa"]
F --> H["Splicing Dysfunction"]
H --> I["Photoreceptor Degeneration"]
H --> J["Neuronal Dysfunction"]
I --> K["Vision Loss"]
J --> L["Neurodegeneration"]